{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:56:02Z","timestamp":1790560562455,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":84,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>HER2-low triple-negative breast cancer (TNBC) has emerged as a clinically relevant subgroup with distinct therapeutic implications. However, the biological mechanisms underlying its heterogeneous response to immunotherapy remain poorly defined. In this manuscript, we conducted a retrospective translational analysis of patients with HER2-zero and HER2-low TNBC. Peripheral blood mononuclear cells (PBMCs) were analyzed by flow cytometry to characterize CD8\u207a T-cell differentiation and functional states. Circulating levels of soluble HER2 extracellular domain (HER2 ECD) were quantified by ELISA, and serum cytokine profiles were assessed using Luminex assays. In vitro assays using tumor-derived conditioned media and purified recombinant HER2 ECD were performed to evaluate the immunomodulatory effects of HER2 antigen exposure. Clinical responses to neoadjuvant chemotherapy with or without PD-1-based immunotherapy were compared between subgroups. In vivo validation was conducted using a syngeneic mouse model. Although the overall proportions of peripheral T cells were comparable between groups, HER2-low TNBC was associated with a shift in CD8\u207a T-cell differentiation toward effector and effector-memory phenotypes, accompanied by increased expression of exhaustion markers. Patients with HER2-low disease exhibited significantly elevated circulating HER2 ECD levels. In vitro, purified recombinant HER2 ECD was sufficient to induce time-dependent activation and subsequent exhaustion-like phenotypes in CD8\u207a T cells, while HER2 blockade in conditioned media partially attenuated these effects. Clinically, HER2-low tumors showed a significantly reduced pathological complete response rate following PD-1-based immunotherapy. Consistently, HER2-targeted therapy enhanced antitumor efficacy and improved CD8\u207a T-cell function when combined with PD-1 blockade in vivo. In summary, HER2-low TNBC is associated with elevated circulating HER2 antigen and a peripheral CD8\u207a T-cell state characterized by progressive differentiation and exhaustion. These findings support a model in which tumor antigen shedding contributes to systemic immune modulation and may limit responsiveness to immunotherapy. Targeting HER2-associated antigen dynamics may represent a potential strategy to improve immunotherapeutic outcomes in HER2-low TNBC.<\/jats:p>","DOI":"10.1038\/s41419-026-09094-1","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:34:25Z","timestamp":1783326865000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Soluble HER2 promotes chronic antigen-mediated CD8\u207a T-cell dysfunction and limits immunotherapy response in HER2-low triple-negative breast cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Lanyu","family":"Jing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3998-1198","authenticated-orcid":false,"given":"Anze","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5923-3306","authenticated-orcid":false,"given":"Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"9094_CR1","doi-asserted-by":"publisher","first-page":"218225","DOI":"10.1016\/j.canlet.2025.218225","volume":"639","author":"M Safaei","year":"2026","unstructured":"Safaei M, Li YC, Chen CY, Hsieh PH, Venkataraman S, Huang WC, et al. Targeting ephrin receptor A10 with antibody-drug conjugates for breast cancer. Cancer Lett. 2026;639:218225.","journal-title":"Cancer Lett"},{"key":"9094_CR2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.cell.2026.01.001","volume":"189","author":"SW Zhang","year":"2026","unstructured":"Zhang SW, Wang H, Xiao Y, Liu LT, Shen M, Wang Z, et al. Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment. Cell. 2026;189:1039\u201355.e20.","journal-title":"Cell"},{"key":"9094_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02547-9","volume":"25","author":"O Castellanet","year":"2026","unstructured":"Castellanet O, Monatte J, Corvaisier N, Kaoutari AE, Kaya M, Ferreira L, et al. Multi-omics profiling uncovers immune-molecular clusters with distinct chemo-immunotherapeutic vulnerabilities in a mouse model of triple-negative breast cancer. Mol Cancer. 2026;25:35.","journal-title":"Mol Cancer"},{"key":"9094_CR4","doi-asserted-by":"crossref","unstructured":"Xiao Y\u8096, Xu Y\u5f90, Wang H\u738b, Yang F\u6768, Ding XH\u4e01, Fu T\u5085, et al. HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer. Cell Metab. 2025;37:2030\u201347.","DOI":"10.1016\/j.cmet.2025.08.009"},{"key":"9094_CR5","doi-asserted-by":"crossref","unstructured":"M\u00f8ldrup RIJ, Terp MG, Jakobsen ST, Ravnsborg T, Madsen MS, Brown DD, et al. SWI\/SNF functions as a gatekeeper of enhancer chromatin access to control progression of mesenchymal triple-negative breast cancer. Cancer Res. 2025;85:4648\u2013466.","DOI":"10.1158\/0008-5472.CAN-24-1660"},{"key":"9094_CR6","doi-asserted-by":"crossref","unstructured":"Avellino A, Jiang X, Lee M, Yu J, Liu S, Han X, et al. An olive oil-based high-fat diet promotes obesity-driven metastasis of triple-negative breast cancer. Cancer Res. 2025;85:5015\u201332.","DOI":"10.1158\/0008-5472.CAN-25-0822"},{"key":"9094_CR7","doi-asserted-by":"publisher","first-page":"e70154","DOI":"10.1002\/jev2.70154","volume":"14","author":"H Wang","year":"2025","unstructured":"Wang H, Huang R, Luo L, Wang R, Zhou Z, Hong J, et al. Targeting reticulin 4 (RTN4) within small extracellular vesicles combats metastasis and reinforces immunotherapy in triple-negative breast cancer. J Extracell Vesicles. 2025;14:e70154.","journal-title":"J Extracell Vesicles"},{"key":"9094_CR8","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1200\/JCO-24-01960","volume":"43","author":"JC Dickerson","year":"2025","unstructured":"Dickerson JC, Moen MT, Nielsen P Jr., Riaz F, Tran E, Caswell-Jin JL, et al. Cost and cost-effectiveness of treating human epidermal growth factor receptor 2-low metastatic breast cancer. J Clin Oncol. 2025;43:2208\u201317.","journal-title":"J Clin Oncol"},{"key":"9094_CR9","doi-asserted-by":"publisher","first-page":"102865","DOI":"10.1016\/j.ctrv.2024.102865","volume":"132","author":"F Schettini","year":"2025","unstructured":"Schettini F, Nucera S, Pascual T, Mart\u00ednez-S\u00e1ez O, S\u00e1nchez-Bayona R, Conte B, et al. Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: a systematic review and network meta-analysis. Cancer Treat Rev. 2025;132:102865.","journal-title":"Cancer Treat Rev"},{"key":"9094_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1093\/neuonc\/noae163","volume":"27","author":"AM Pereslete","year":"2025","unstructured":"Pereslete AM, Hughes ME, Martin AR, Files J, Nguyen K, Buckley L, et al. Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival. Neuro Oncol. 2025;27:184\u201394.","journal-title":"Neuro Oncol"},{"key":"9094_CR11","doi-asserted-by":"publisher","first-page":"e03925","DOI":"10.1002\/advs.202503925","volume":"12","author":"X Zhang","year":"2025","unstructured":"Zhang X, Shen YY, Su GH, Guo Y, Zheng RC, Du SY, et al. A dynamic contrast-enhanced MRI-based vision transformer model for distinguishing HER2-zero, -low, and -positive expression in breast cancer and exploring model interpretability. Adv Sci. 2025;12:e03925.","journal-title":"Adv Sci"},{"key":"9094_CR12","doi-asserted-by":"publisher","first-page":"103831","DOI":"10.1016\/j.breast.2024.103831","volume":"78","author":"N Fusco","year":"2024","unstructured":"Fusco N, Viale G. The \u201clows\u201d: update on ER-low and HER2-low breast cancer. Breast. 2024;78:103831.","journal-title":"Breast"},{"key":"9094_CR13","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1158\/1078-0432.CCR-24-1513","volume":"30","author":"E Hamilton","year":"2024","unstructured":"Hamilton E, Galsky MD, Ochsenreither S, Del Conte G, Mart\u00edn M, De Miguel MJ, et al. Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: analysis of the phase Ib DS8201-A-U105 study. Clin Cancer Res. 2024;30:5548\u201358.","journal-title":"Clin Cancer Res"},{"key":"9094_CR14","doi-asserted-by":"publisher","first-page":"104355","DOI":"10.1016\/j.critrevonc.2024.104355","volume":"198","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn M, Pandiella A, Vargas-Castrill\u00f3n E, D\u00edaz-Rodr\u00edguez E, Iglesias-Hernang\u00f3mez T, Mart\u00ednez Cano C, et al. Trastuzumab deruxtecan in breast cancer. Crit Rev Oncol Hematol. 2024;198:104355.","journal-title":"Crit Rev Oncol Hematol"},{"key":"9094_CR15","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1001\/jamaoncol.2022.6889","volume":"9","author":"D Idossa","year":"2023","unstructured":"Idossa D, Borrero M, Blaes A. ERBB2-low (also known as HER2-low) breast cancer. JAMA Oncol. 2023;9:576.","journal-title":"JAMA Oncol"},{"key":"9094_CR16","doi-asserted-by":"publisher","first-page":"102692","DOI":"10.1016\/j.arr.2025.102692","volume":"106","author":"M Li","year":"2025","unstructured":"Li M, Zheng A, Song M, Jin F, Pang M, Zhang Y, et al. From text to insight: a natural language processing-based analysis of burst and research trends in HER2-low breast cancer patients. Ageing Res Rev. 2025;106:102692.","journal-title":"Ageing Res Rev"},{"key":"9094_CR17","doi-asserted-by":"publisher","first-page":"102989","DOI":"10.1016\/j.esmoop.2024.102989","volume":"9","author":"G Curigliano","year":"2024","unstructured":"Curigliano G, Dent R, Earle H, Modi S, Tarantino P, Viale G, et al. Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer. ESMO Open. 2024;9:102989.","journal-title":"ESMO Open"},{"key":"9094_CR18","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.22.02864","volume":"41","author":"AC Wolff","year":"2023","unstructured":"Wolff AC, Somerfield MR, Dowsett M, Hammond MEH, Hayes DF, McShane LM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists Guideline Update. J Clin Oncol. 2023;41:3867\u201372.","journal-title":"J Clin Oncol"},{"key":"9094_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40715-x","volume":"14","author":"LJ Dai","year":"2023","unstructured":"Dai LJ, Ma D, Xu YZ, Li M, Li YW, Xiao Y, et al. Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer. Nat Commun. 2023;14:5112.","journal-title":"Nat Commun"},{"key":"9094_CR20","doi-asserted-by":"publisher","first-page":"e172366","DOI":"10.1172\/jci.insight.172366","volume":"8","author":"L Chen","year":"2023","unstructured":"Chen L, Liu CC, Zhu SY, Ge JY, Chen YF, Ma D, et al. Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects. JCI Insight. 2023;8:e172366.","journal-title":"JCI Insight"},{"key":"9094_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320.","journal-title":"N Engl J Med"},{"key":"9094_CR22","doi-asserted-by":"publisher","first-page":"7248","DOI":"10.1016\/j.cell.2024.09.032","volume":"187","author":"L Xu","year":"2024","unstructured":"Xu L, Peng F, Luo Q, Ding Y, Yuan F, Zheng L, et al. IRE1\u03b1 silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. Cell. 2024;187:7248\u201366.e34.","journal-title":"Cell"},{"key":"9094_CR23","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.annonc.2025.08.005","volume":"36","author":"PF Conte","year":"2025","unstructured":"Conte PF, Dieci MV, Bisagni G, Schmid P, Zambelli A, Piacentini F, et al. A-BRAVE trial: a phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients. Ann Oncol. 2025;36:1492\u2013502.","journal-title":"Ann Oncol"},{"key":"9094_CR24","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.ccell.2025.06.019","volume":"43","author":"L Meyer","year":"2025","unstructured":"Meyer L, Jackson HW, Eling N, Zhao S, Usui G, Dakhli H, et al. A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture. Cancer Cell. 2025;43:1637\u201355.e9.","journal-title":"Cancer Cell"},{"key":"9094_CR25","doi-asserted-by":"crossref","unstructured":"Arora A, Bhaskarane H, Tansir G, Bakhshi S, Gogia A, Kumar A, et al. A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low dose in Addition to NACT in TNBC). Ann Oncol. 2025;37:639\u201349.","DOI":"10.1016\/j.annonc.2025.12.015"},{"key":"9094_CR26","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. 2024;391:1981\u201391.","journal-title":"N Engl J Med"},{"key":"9094_CR27","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41571-022-00674-6","volume":"19","author":"D Romero","year":"2022","unstructured":"Romero D. KEYNOTE-355 - OS benefit now reported. Nat Rev Clin Oncol. 2022;19:616.","journal-title":"Nat Rev Clin Oncol"},{"key":"9094_CR28","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41423-025-01316-4","volume":"22","author":"K Peng","year":"2025","unstructured":"Peng K, Zhao X, Fu YX, Liang Y. Eliciting antitumor immunity via therapeutic cancer vaccines. Cell Mol Immunol. 2025;22:840\u201368.","journal-title":"Cell Mol Immunol"},{"key":"9094_CR29","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41423-025-01321-7","volume":"22","author":"D Zou","year":"2025","unstructured":"Zou D, Li XC, Chen W. Beyond T-cell subsets: stemness and adaptation redefining immunity and immunotherapy. Cell Mol Immunol. 2025;22:957\u201374.","journal-title":"Cell Mol Immunol"},{"key":"9094_CR30","doi-asserted-by":"crossref","unstructured":"Huang H, Ma W, Zeng X, Liu B, Dai H, Zhou G, et al. Efficacy and safety of disitamab vedotin combined with gemcitabine as neoadjuvant therapy in muscle-invasive bladder cancer: an open-label, multicenter, single-arm, phase 2 trial. Eur Urol. 2025;S0302-2838:04768-2.","DOI":"10.1016\/j.eururo.2025.10.009"},{"key":"9094_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41392-024-02047-0","volume":"9","author":"Z Yi","year":"2024","unstructured":"Yi Z, Feng K, Lv D, Guan Y, Shao Y, Ma F, et al. Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer. Signal Transduct Target Ther. 2024;9:345.","journal-title":"Signal Transduct Target Ther"},{"key":"9094_CR32","doi-asserted-by":"publisher","first-page":"103973","DOI":"10.1016\/j.esmoop.2024.103973","volume":"9","author":"AS Raghavendra","year":"2024","unstructured":"Raghavendra AS, Zakon DB, Jin Q, Strahan A, Grimm M, Hughes ME, et al. Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy according to HER2-low status\u2729. ESMO Open. 2024;9:103973.","journal-title":"ESMO Open"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09094-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09094-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09094-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:16:57Z","timestamp":1790558217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-09094-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9094"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-09094-1","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study followed all dictates of the Declaration of Helsinki and the Ethics Committee for Clinical research and animal trials of the First Affiliated Hospital of Sun Yat-sen University and Guangdong Provincial Hospital of Chinese Medicine. The approval numbers are [2022]-242 and 2026-348.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors agree to publish the manuscript.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"838"}}